Explore how Takeda is implementing new predictive toxicology methods to improve drug safety and accelerate development. David Gallegos from Takeda’s Investigative Toxicology team shares how they are advancing neurotoxicity screening with the 28bio cortical brain organoid model that exhibits robust spontaneous calcium waveform activity, is compatible with high-throughput screening methodologies, and provides a clinically relevant endpoint for phenotypic profiling.

‍

Key Takeaways

‍

• Why detecting neurotoxicity before the clinic is one of the toughest hurdles in drug development

• The role of CNS-3D organoids in enabling high-throughput, human-relevant neurotoxicity screening for small molecules

• The application of iPSC-derived 3D neural models to monitor compound-induced calcium oscillation changes

• The use of logistic regression to improve precision in categorizing compounds’ neurotoxic potential across multiple endpoints

• The potential of machine learning to refine predictive power and expand visibility into toxicological risk

‍

Speaker

‍

David A, Gallegos, PhD

Senior Scientist, Investigative Toxicology Team & Department of Drug Safety Research and Evaluation, Takeda Pharmaceuticals